GC/MS based metabolic profiling of lung cancer and treatment in mice
Abstract
GC/MS based metabolite profiling was used to explore potential metabolite biomarkers for Madison lung carcinoma 109 (M109) in Balb/c mice. Newly discovered biomarkers could be beneficial to both detection and follow up therapy with novel antitumor agents such as EC0225. Metabolites that were statistically significant and showed meaningful trends in duplicate analyses were categorized into two main groups. In the first group, the metabolite signal intensity decreased after tumor growth, but increased after treatment with EC0225, while in the second group the intensity increased after tumor inoculation and decreased after EC0225 was applied. Urine from mice with M109 tumors showed elevated levels of quinolinic acid, phenylpyruvic acid, 2, 3-dihydroxybenzoic acid, and lactic acid. In addition, these samples showed lower levels of oxalic acid, L-homoserine, and 4-hydroxy-3-methoxybenzoic acid. These results are valuable for understanding the metabolic basis of tumorigenesis and its possible reversal with drug therapy. The validation of these potential metabolite biomarkers could enhance the application and efficacy of existing and new treatment methods against the deadliest cancer.
Degree
M.S.
Advisors
Raftery, Purdue University.
Subject Area
Chemistry|Analytical chemistry|Biochemistry
Off-Campus Purdue Users:
To access this dissertation, please log in to our
proxy server.